CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Bronstein, Gewirtz & Grossman, LLC Is Investigating Foghorn Therapeutics Inc. (FHTX) And Encourages Stockholders to Connect

By ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / October 15, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Foghorn Therapeutics Inc. ("Foghorn" or "the Company") (NASDAQ:FHTX). Investors who purchased Foghorn securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/foghorn-therapeutics-inc-fhtx-class_action_lawsuit.

Foghorn Investigation Details

On October 1, 2026, Foghorn Therapeutics Inc. announced that, following a review of clinical data from the Phase 1 dose-escalation trial of FHD-909 (LY4050784), the Company and its collaboration partner, Eli Lilly, decided not to advance the program into the clinical development expansion phase. The companies also decided to discontinue development of their Selective SMARCA2 degrader program and indicated that they did not anticipate further collaboration activities. As a result, Foghorn stated that it would prioritize resources toward its proprietary portfolio programs. Following this news, Foghorn's stock price declined more than 30.8% on October 2, 2026.

What's Next for Foghorn Investors?

If you are aware of any facts relating to this investigation or purchased Foghorn securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/foghorn-therapeutics-inc-fhtx-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Foghorn Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Foghorn Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk